Fresenius Medical Care AG & Co. KGaA (FMS) Cash Flow Statement
Where FMS’s cash came from and went, 2025
December 31, 2025 · euros- Cash from operations
- €2.58B +7.9% vs 2024
- Capital expenditures
- €879.2M 4.5% of revenue
- Free cash flow
- €1.70B 8.6% margin
- Returned to shareholders
- €968.0M 57% of free cash flow
- Change in cash
- €558.3M cash at year-end €1.60B
Drawn to scale: where the cash came from and how it was used. Hover for values.
FMS operating cash flow, capex and free cash flow
FMS cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | €2.03B2016 | €2.58B2025 | +2.7%/yr | |
| Capital expenditures | €1.94B2016 | €879.2M2025 | −8.4%/yr | |
| Free cash flow | €93.2M2016 | €1.70B2025 | +38.0%/yr | |
| Free cash flow margin | 0.5%2016 | 8.6%2025 | +8.1 pts | |
| Operating cash flow / net income | 1.382016 | 2.742025 | +1.36 | |
| Stock-based compensation | €28.7M2016 | €32.5M2023 | +1.8%/yr | |
| Dividends paid | €263.6M2016 | €405.8M2025 | +4.9%/yr | |
| Share buybacks (net) | €02016 | €562.2M2025 | — | |
| Capex / revenue | 11.4%2016 | 4.5%2025 | −6.9 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
FMS cash flow by activity
FMS net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
FMS cash flow statement in euros
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | €939.8M | €740.9M | €732.5M | €895.0M | €1.22B | €1.44B | €1.44B | €2.23B | €1.55B | €1.47B |
| Depreciation & amortization | €1.50B | €1.74B | €1.75B | €1.84B | €1.62B | €1.79B | €1.59B | €736.4M | €735.5M | €701.5M |
| Stock-based compensation | — | — | €32.5M | −€5.9M | −€1.69B | −€1.90B | €2.0M | €10.7M | €46.8M | €28.7M |
| Change in working capital | €132.8M | €444.3M | €561.3M | −€566.0M | −€354.0M | €1.01B | −€465.0M | −€889.0M | −€98.0M | −€175.0M |
| Other non-cash items | €2.2M | −€541.3M | −€449.4M | €5.5M | €1.69B | €1.90B | −€2.0M | −€22.2M | −€46.3M | €6.7M |
| Cash from operating activities | €2.58B | €2.39B | €2.63B | €2.17B | €2.49B | €4.23B | €2.57B | €2.06B | €2.19B | €2.03B |
| Investing activities | ||||||||||
| Capital expenditures | −€879.2M | −€699.4M | −€684.6M | −€1.41B | −€1.68B | −€2.09B | −€2.24B | −€2.06B | −€1.78B | −€1.94B |
| Investments (net) | −€4.0M | −€84.9M | −€672.7M | −€734.7M | −€61.6M | −€1.33B | −€3.29B | −€245.0M | −€991.5M | −€1.31B |
| Acquisitions & other investing | €217.1M | €699.4M | €813.0M | €1.41B | €548.3M | €2.09B | €2.24B | €2.06B | €1.78B | €1.94B |
| Cash from investing activities | −€666.2M | −€84.9M | −€544.2M | −€734.7M | −€1.20B | −€1.33B | −€3.29B | −€245.0M | −€991.5M | −€1.31B |
| Financing activities | ||||||||||
| Dividends paid | −€405.8M | −€349.2M | −€328.6M | −€395.6M | −€392.5M | −€351.2M | −€354.6M | −€324.8M | −€294.0M | −€263.6M |
| Share repurchases & issuance (net) | −€562.2M | €0 | €0 | €20.2M | €6.5M | −€366.0M | −€599.8M | −€37.2M | −€57.9M | €47.5M |
| Net borrowing (repayment) | €149.6M | −€1.91B | −€1.19B | −€1.02B | −€358.9M | −€1.64B | €700.0M | −€138.0M | −€150.8M | −€100.5M |
| Shares issued | €0 | €0 | €0 | €0 | €0 | €0 | €0 | €0 | €0 | €0 |
| Other financing | −€557.2M | −€315.0M | −€340.1M | −€218.9M | −€279.5M | −€307.0M | −€212.2M | −€181.7M | −€296.0M | −€239.4M |
| Cash from financing activities | −€1.38B | −€2.57B | −€1.86B | −€1.62B | −€1.02B | −€2.66B | −€466.6M | −€681.7M | −€798.6M | −€556.0M |
| Summary | ||||||||||
| Net change in cash | €558.3M | −€241.9M | €153.4M | −€207.9M | €400.1M | €73.8M | −€1.14B | €1.17B | €269.2M | €188.0M |
| Cash at end of period | €1.60B | €1.19B | €1.43B | €1.27B | €1.48B | €1.08B | €1.01B | €2.15B | €978.1M | €710.5M |
| Free cash flow | €1.70B | €1.69B | €1.94B | €756.0M | €806.0M | €2.15B | €329.0M | €2.0M | €407.0M | €93.2M |
| Free cash flow margin | 8.6% | 8.7% | 10.0% | 3.9% | 4.6% | 12.0% | 1.9% | 0.0% | 2.3% | 0.5% |
| Capex / revenue | 4.5% | 3.6% | 3.5% | 7.3% | 9.6% | 11.7% | 12.8% | 12.4% | 10.0% | 11.4% |
| Operating cash flow / net income | 2.74 | 3.22 | 3.59 | 2.42 | 2.04 | 2.95 | 1.78 | 0.93 | 1.41 | 1.38 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | €293.2M | €164.8M | €327.0M | €274.8M | €272.3M | €189.6M | €66.9M | €213.0M | €187.0M | €118.3M | €256.6M | €84.4M |
| Depreciation & amortization | €363.1M | €462.9M | €373.6M | €357.3M | €375.2M | €394.4M | €477.0M | €366.3M | €387.0M | €512.4M | €425.9M | €392.4M |
| Stock-based compensation | — | — | — | — | — | — | €38.5M | — | — | — | €32.5M | −€227.4M |
| Change in working capital | €297.2M | −€358.0M | €147.4M | −€278.3M | €281.9M | −€385.0M | €4.5M | €500.6M | −€87.1M | −€420.8M | €122.2M | €2.9M |
| Other non-cash items | −€93.1M | −€42.8M | €126.6M | €387.8M | −€154.5M | −€36.1M | €244.8M | −€95.2M | −€44.5M | −€82.6M | −€118.2M | €507.5M |
| Cash from operating activities | €860.3M | €226.9M | €974.5M | €741.6M | €774.9M | €162.8M | €831.7M | €984.7M | €442.4M | €127.3M | €719.1M | €759.8M |
| Investing activities | ||||||||||||
| Capital expenditures | −€240.4M | −€190.1M | −€410.4M | −€192.2M | −€154.4M | −€145.8M | −€240.7M | −€165.4M | −€159.4M | −€133.9M | −€250.3M | −€136.8M |
| Investments (net) | −€32.8M | €20.6M | −€35.5M | €273.7M | −€142.1M | −€108.2M | −€9.2M | €600.3M | −€306.0M | −€68.4M | −€96.5M | −€151.1M |
| Acquisitions & other investing | €2.4M | −€56,000 | €49.6M | −€135.5M | €154.4M | €145.8M | €130.7M | −€654.8M | €788.0M | €133.9M | €250.3M | €136.8M |
| Cash from investing activities | −€270.8M | −€169.5M | −€396.3M | −€54.0M | −€142.1M | −€108.2M | −€119.2M | −€219.9M | €322.6M | −€68.4M | −€96.5M | −€151.1M |
| Financing activities | ||||||||||||
| Dividends paid | — | — | −€2.2M | −€422.5M | −€422.5M | — | −€349.2M | −€349.2M | −€349.2M | — | €0 | −€328.6M |
| Share repurchases & issuance (net) | −€144.6M | −€347.3M | −€419.4M | −€151.1M | €0 | €0 | €0 | — | — | — | — | €0 |
| Net borrowing (repayment) | −€147.0M | −€16.3M | €285.7M | −€604.3M | €547.2M | −€79.0M | −€837.8M | — | — | — | — | −€342.1M |
| Shares issued | €0 | €0 | €0 | €0 | €0 | €0 | €0 | €0 | €0 | €0 | €0 | €0 |
| Other financing | −€477.9M | −€72.5M | −€79.8M | €42.7M | −€45.4M | −€59.8M | €221.8M | −€127.9M | −€488.2M | −€289.7M | −€745.7M | €258.3M |
| Cash from financing activities | −€769.5M | −€436.1M | −€215.6M | −€1.14B | €79.2M | −€138.8M | −€965.2M | −€477.1M | −€837.4M | −€289.7M | −€745.7M | −€412.3M |
| Summary | ||||||||||||
| Net change in cash | −€177.9M | −€360.0M | €342.4M | −€463.9M | €641.4M | −€106.6M | −€201.9M | €275.3M | −€80.1M | −€235.2M | −€147.1M | €213.1M |
| Cash at end of period | €1.06B | €1.24B | €1.60B | €1.26B | €1.72B | €1.08B | €1.19B | €1.39B | €1.11B | €1.19B | €1.43B | €1.57B |
| Free cash flow | €619.9M | €36.8M | €564.1M | €549.3M | €620.5M | €17.1M | €591.0M | €819.4M | €283.0M | −€6.6M | €468.8M | €623.0M |
| Free cash flow margin | 12.8% | 0.8% | 11.1% | 11.2% | 13.0% | 0.3% | 11.6% | 17.2% | 5.9% | −0.1% | 9.4% | 12.6% |
| Capex / revenue | 4.9% | 4.1% | 8.1% | 3.9% | 3.2% | 3.0% | 4.7% | 3.5% | 3.3% | 2.8% | 5.0% | 2.8% |
| Operating cash flow / net income | 2.93 | 1.38 | 2.98 | 2.70 | 2.85 | 0.86 | 12.43 | 4.62 | 2.37 | 1.08 | 2.80 | 9.01 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in euros as reported; data from EODHD.
FMS cash generation
In fiscal 2025 (ended December 31, 2025), Fresenius Medical Care AG & Co. KGaA generated €2.6 billion of cash from operations (up 7.9%) and spent €879.2 million on capital expenditures, leaving free cash flow of €1.7 billion, 8.6% of revenue. It returned €968.0 million to shareholders through dividends (€405.8 million) and net share buybacks (€562.2 million). Cash and equivalents rose by €558.3 million over the year.
Related: FMS income statement, FMS balance sheet, FMS dividend history. See the FMS stock overview for the latest quote and news.
FMS cash flow FAQ
What is Fresenius Medical Care AG & Co. KGaA's free cash flow?
Fresenius Medical Care AG & Co. KGaA's free cash flow was €1.7 billion in fiscal 2025: €2.6 billion of operating cash flow minus €879.2 million of capital expenditures It was €1.7 billion a year earlier..
How much cash does Fresenius Medical Care AG & Co. KGaA generate from operations?
Fresenius Medical Care AG & Co. KGaA generated €2.6 billion of cash from operating activities in fiscal 2025, 2.74 times its net income of €939.8 million.
How much does Fresenius Medical Care AG & Co. KGaA spend on capital expenditures?
Fresenius Medical Care AG & Co. KGaA spent €879.2 million on capital expenditures in fiscal 2025, 4.5% of revenue, compared with €699.4 million the year before.
How much stock does Fresenius Medical Care AG & Co. KGaA buy back?
Fresenius Medical Care AG & Co. KGaA spent €562.2 million on net share repurchases in fiscal 2025.
How much does Fresenius Medical Care AG & Co. KGaA pay in dividends?
Fresenius Medical Care AG & Co. KGaA paid €405.8 million in dividends in fiscal 2025, 23.9% of free cash flow.